TG Therapeutics (TGTX) reported a Q4 net income Monday of $0.15 per diluted share, swinging from loss of $0.10 a year earlier.
Analysts polled by FactSet expected earnings of $0.16.
Revenue for the quarter ended Dec. 31 was $108.2 million, up from $44 million a year earlier.
Analysts surveyed by FactSet expected $100.7 million.
The company said it expects full-year 2025 revenue of around $540 million. Analysts polled by FactSet expect $534.4 million.
As of Dec. 31, the company said it had $311 million in cash, cash equivalents and investment securities, which combined with the expected revenue from Briumvi, will be "sufficient" to fund the company's business based on its current operating plan.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。